title: Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Cultured Non-Small Cell Lung Cancer Cells.
abstract: Tumor suppressor miRNAs such as miR-34a inhibit tumor growth by simultaneously regulating the expression of multiple important oncogenes across multiple oncogenic pathways and, therefore, provide a strong rationale for developing therapeutic miRNA mimics in combination with other therapeutic cancer agents to augment drug sensitivity. Here, we describe the experimental approach for evaluating miRNA and drug combinations using the "fixed ratio" method in cultured non-small cell lung cancer cells.
authors.affiliation: Mirna Therapeutics, Inc., 2150 Woodward Street, Suite 100, Austin, TX, 78744, USA.
authors.forename: Jane
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Mirna Therapeutics, Inc., 2150 Woodward Street, Suite 100, Austin, TX, 78744, USA. abader@mirnarx.com.
authors.forename: Andreas G
authors.initials: AG
authors.lastname: Bader
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism
chemical_list: C522425:MIRN34 microRNA, human; D035683:MicroRNAs
keywords: Combination index; Combination therapy; Dose reduction index; MRX34; miR-34a; miRNA therapeutics